CMC and Clinical Strategies for the Successful Development of Injectable and Oral Peptide Drugs: San Diego, CA

Join us for an enlightening seminar on the latest developments in oral peptides with our Chief Scientific Officer, Dr. Andrew Lewis.

Our next seminar will explore critical drivers and innovative delivery options for peptide drugs. Hear about these topics and more from our speaker:

• The clinical development strategies to switch delivery routes from intravenous to subcutaneous administration
• Strategies to phase CMC investment to reduce risk and meet the the target product profile (TPP) of your drug
• The role of rapid clinical pharmacokinetic prototyping to optimize peptide product development

Dr. Lewis will highlight CMC and clinical learnings from over 14 oral peptide programs evaluating 10 different permeation enhancers that Quotient Sciences has worked on over the past decade, with insights from the use of PBPK modelling to inform oral peptide development.

Register now